Navrogen Presents Preclinical Data on NAV-001 Antibody-Drug Conjugate and NAV-003 Bispecific Programs at the 2023 American Association for Cancer Research Annual Meeting

/PRNewswire/ -- Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, will be presenting new...

Related Keywords

United States ,American ,Steven Kyriakos ,Luigi Grasso ,Nicholas Nicolaides ,Navrogen Incorporated ,Prnewswire Navrogen Inc ,American Association For Cancer Research ,Cancer Research ,Humoral Immuno Oncology ,Chief Scientific ,Chief Executive Officer ,Navrogen ,Ncorporated ,